Sold as Aminosyn 3.5% W/ Dextrose 25% In Plastic Container, Aminosyn 4.25% W/ Dextrose 25% In Plastic Container, Aminosyn 3.5% W/ Dextrose 5% In Plastic Container, Aminosyn Ii 4.25% In Dextrose 25% In Plastic Container, Aminosyn Ii 3.5% In Dextrose 25% In Plastic Container and 27 more. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 11 applications for Amino Acids; Dextrose (sold as Aminosyn 3.5% W/ Dextrose 25% In Plastic Container, Aminosyn 4.25% W/ Dextrose 25% In Plastic Container, Aminosyn 3.5% W/ Dextrose 5% In Plastic Container and others), first approved Dec 17, 1986, with 2 new uses approved and 0 published complete response letters.
| FEAST and HOPE: Redox PSC Pilot StudyPrimary Sclerosing Cholangitis (PSC) · Brigham and Women's Hospital | Phase 2 | Not yet recruiting | Oct 27, 2026 |
| A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering MedicationsType 2 Diabetes Mellitus · Hoffmann-La Roche | Phase 3 | Not yet recruiting | Oct 22, 2026 |
| Amino Acid Therapy Evaluating the Incidence of New-Onset AKIAcute Kidney Injury · Children's Hospital Medical Center, Cincinnati | Phase 2 | Not yet recruiting | Oct 19, 2026 |
| Effects of Pre-Run Nutritional Supplements During a Fixed-Pace 5 km Treadmill RunExercise Physiology, Nutritional Supplementation · St. Louis University | Not applicable | Recruiting | Oct 2, 2026 |
| Hypothalamic GLP-1 Response in Healthy Weight and ObesityObesity, Normal Weight · University of Copenhagen | Not applicable | Recruiting | Oct 2, 2026 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or OverweightChronic Weight Management · Ascletis Pharma (China) Co., Limited | Phase 1 | Recruiting | Sep 25, 2026 |
| Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)Hypoglycemia, Hypoglycemia, Reactive · Joslin Diabetes Center | Phase 4 | Recruiting | Sep 14, 2026 |
| Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial CancerGrade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia · Milton S. Hershey Medical Center | Early phase 1 | Not yet recruiting | Sep 10, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA